Discovery of 4-[3-(trans-3-Dimethylaminocyclobutyl)-1H-indol-5-ylmethyl](4S)-oxazolidin- 2-one (4991W93), a 5HT1b/1d receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation

Journal of Medicinal Chemistry

Volumn 44, Issue 5, 2001, Pages 681-693

  Jandu, K S ^c   Barrett, V ^c   Brockwell, M ^c   Cambridge, D ^c   Farrant, D R ^c   Foster, C ^c   Giles, H ^c   Glen, R C ^b   Hill, A P ^c   Hobbs, H ^c   Honey, A ^c   Martin, G R ^d   Salmon, J ^e   Smith, D ^c   Woollard, P ^c   Selwood, D L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d ROCHE BIOSCIENCE   (United States)

^e Roche Bioscience ^*

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (3 DIMETHYLAMINOCYCLOBUTYL) 1H INDOL 5 YLMETHYL]OXAZOLIDIN 2 ONE; 4991W93; 5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; NARATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D AGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CATTLE; CHEMOMETRICS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EXTRAVASATION; GUINEA PIG; HUMAN; MALE; MIGRAINE; NONHUMAN; RABBIT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL AVAILABILITY; BRAIN; CAPILLARY PERMEABILITY; CATTLE; CHO CELLS; CRICETINAE; EAR; ELECTRIC STIMULATION; GUINEA PIGS; HUMANS; INDOLES; MALE; MIGRAINE DISORDERS; MODELS, MOLECULAR; OXAZOLES; RABBITS; RATS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; REGIONAL BLOOD FLOW; SEROTONIN AGONISTS; SERUM ALBUMIN, BOVINE; STRUCTURE-ACTIVITY RELATIONSHIP; TRIGEMINAL GANGLION; VASOCONSTRICTOR AGENTS;

EID: 0035282627     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000956k     Document Type: Article

References (36)

1. Second generation antimigraine 5HT1B/1D agonists: Structure activity relationship and preclinical pharmacological considerations
2. Naratriptan
3. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: Demonstration of a central effect for the 5HT1B/1D agonis zolmitriptan (311C90, Zomig)
4. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat
5. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine
6. 1B/1D receptor: A central action in migraine
7. 1B immunoreactivity within the human trigemino-cerebrovascular system: Implications for the discovery of new antimigraine drugs
8. Differential effects on neurogenic dural plasma extravasation and vasodilatiation in anaethetized rats
9. Serotonin receptors and the acute attack of migraine
10. CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: Results of two controlled clinical trials
11. Advances in the pharmacotherapy of migraine
12. 1F receptor agonist LY334370
13. Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine
14. Rhodium-catalysed hydroformylation of allyl alcohol. A potential route to 1,4-butanediol
15. Synthesis and serotonergic activity of substituted 2,N-benzylcarboxamido-5-(2-ethyl-1-dioxoimidazolidinyl)-N,N- dimethyltryptamine derivatives: Novel antagonists for the vascular 5-HT(1B)-like receptor
16. New synthesis of 1,2,4-triazoles and 1,2,4-oxadiazoles
17. Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan
18. Oral delivery of 5-HT1D receptor agonists: Towards the discovery of 311C90, a novel anti-migraine agent
19. 1B/1D agonists
20. Computeraided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: Discovery of compounds with potential anti-migraine properties
21. Synthesis and pharmacological profile of a series of 2,5substituted-N,N-dimethyltryptamine derivatives as novel antagonists for the vascular 5-HT1B-like receptor
22. Special Report
23. Analysis of 5HT receptors and the design of therapeutic analogues
24. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan)
25. Analysis of the 5-HT receptor in rabbit saphenous vein exemplified the problems of using exclusion criteria for receptor classification
26. A study to investigate the tolerability, pharmacokinetics and effects on blood pressure, heart rate and substance P-induced wheal and flare response of single, oral doses of 4991W93 in healthy volunteers
27. Current and emerging second generation triptans in acute migraine therapy: A comparative review
28. 1B/1D agonist doses of 4991W93 inhibit CGRP release in the cat
29. Microinotophoretic application of 4991W93 inhibits trigeminocervical neurons
30. Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine
31. Rapid chromatographic technique for preparative separations with moderate resolution
32. 4-Hydroxy-2-methyl-3(2H)-isothiazolone-1,1-dioxide as a protecting group of 4-(N-methylaminosulphonyl)methylphenylhydrazone during Fischer indole synthesis